Kinetics of solvent extraction/evaporation process for PLGA microparticle fabrication.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 18782610)

Published in Int J Pharm on August 22, 2008

Authors

Hajime Katou1, Anne Julia Wandrey, Bruno Gander

Author Affiliations

1: Tsuchiura Research Laboratory, Hitachi Plant Technologies Ltd., 603 Kandatsu, Tsuchiura, Ibaraki 300-0013, Japan. hajime.kato.sx@hitachi-pt.com

Articles by these authors

Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J Control Release (2005) 2.17

Localized delivery of growth factors for bone repair. Eur J Pharm Biopharm (2004) 1.30

Nerve conduits and growth factor delivery in peripheral nerve repair. J Peripher Nerv Syst (2007) 1.29

TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine (2008) 1.26

Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev (2005) 1.22

Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J Control Release (2010) 1.20

Silk fibroin matrices for the controlled release of nerve growth factor (NGF). Biomaterials (2007) 1.17

Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine (2003) 1.14

Localized insulin-like growth factor I delivery to enhance new bone formation. Bone (2003) 1.12

Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today (2011) 1.10

Schwann cell delivery of neurotrophic factors for peripheral nerve regeneration. J Peripher Nerv Syst (2010) 1.07

Synergistic effect of GDNF and NGF on axonal branching and elongation in vitro. Neurosci Res (2009) 1.05

Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine (2005) 1.05

In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur J Pharm Sci (2002) 1.01

Growth factor delivery systems and repair strategies for damaged peripheral nerves. J Control Release (2011) 0.99

Collagen nerve conduits releasing the neurotrophic factors GDNF and NGF. J Control Release (2009) 0.98

Lympho-geographical concepts in vaccine delivery. J Control Release (2010) 0.97

Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J Drug Target (2009) 0.97

Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice. J Antimicrob Chemother (2005) 0.92

Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Methods Mol Med (2005) 0.89

Miconazole nanosuspensions: Influence of formulation variables on particle size reduction and physical stability. Int J Pharm (2010) 0.89

Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J Immunol Methods (2004) 0.88

Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes. J Antimicrob Chemother (2004) 0.88

Effect of controlled co-delivery of synergistic neurotrophic factors on early nerve regeneration in rats. Biomaterials (2010) 0.87

Controlled nerve growth factor release from multi-ply alginate/chitosan-based nerve conduits. Eur J Pharm Biopharm (2008) 0.86

Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. J Control Release (2008) 0.86

Ultrasonic atomisation into reduced pressure atmosphere--envisaging aseptic spray-drying for microencapsulation. J Control Release (2004) 0.86

One-step preparation of polyelectrolyte-coated PLGA microparticles and their functionalization with model ligands. J Control Release (2005) 0.85

Continuous contact- and contamination-free ultrasonic emulsification-a useful tool for pharmaceutical development and production. Ultrason Sonochem (2004) 0.85

The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials (2006) 0.85

Variations in glial cell line-derived neurotrophic factor release from biodegradable nerve conduits modify the rate of functional motor recovery after rat primary nerve repairs. Eur J Neurosci (2007) 0.84

In vivo uptake of an experimental microencapsulated diphtheria vaccine following sub-cutaneous immunisation. Vaccine (2004) 0.83

A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm Res (2007) 0.82

Biodegradable microspheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice. J Control Release (2005) 0.82

Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres. J Control Release (2004) 0.82

Insulin-like growth factor I-releasing alginate-tricalciumphosphate composites for bone regeneration. Pharm Res (2005) 0.81

Development of synthetic biodegradable microparticulate vaccines: a roller coaster story. Expert Rev Vaccines (2007) 0.81

Encapsulation of antigen in poly(D,L-lactide-co-glycolide) microspheres protects from harmful effects of γ-irradiation as assessed in mice. Eur J Pharm Biopharm (2011) 0.81

An experimental divalent vaccine based on biodegradable microspheres induces protective immunity against tetanus and diphtheria. J Pharm Sci (2003) 0.80

Hydrogel nerve conduits produced from alginate/chitosan complexes. J Biomed Mater Res A (2007) 0.80

On technological and immunological benefits of multivalent single-injection microsphere vaccines. Pharm Res (2002) 0.80

Tumor eradication by immunotherapy with biodegradable PLGA microspheres--an alternative to incomplete Freund's adjuvant. Int J Cancer (2011) 0.79

Formulation and drying of miconazole and itraconazole nanosuspensions. Int J Pharm (2013) 0.79

Childhood and malaria vaccines combined in biodegradable microspheres produce immunity with synergistic interactions. J Control Release (2004) 0.78

Nerve conduit scaffolds for discrete delivery of two neurotrophic factors. Eur J Pharm Biopharm (2013) 0.77

Impact of IGF-I release kinetics on bone healing: a preliminary study in sheep. Eur J Pharm Biopharm (2013) 0.77

Effect of oil-in-water emulsions on 5-aminolevulinic acid uptake and metabolism to PpIX in cultured MCF-7 cells. Pharm Res (2004) 0.76

Flow-through ultrasonic emulsification combined with static micromixing for aseptic production of microspheres by solvent extraction. Eur J Pharm Biopharm (2005) 0.76

Polyelectrolyte LbL microcapsules versus PLGA microparticles for immunization with a protein antigen. J Control Release (2011) 0.76

Simultaneous quantification of polymeric and surface active stabilizers of nanosuspensions by using near-infrared spectroscopy. Drug Dev Ind Pharm (2012) 0.75

Development of a novel casein-protamine based microparticles for early feeding of fish larvae: in vitro evaluation. J Microencapsul (2007) 0.75

Foreword - In honor of Prof. em. Dr. Hans Peter Merkle on the occasion of his 70th birthday. Eur J Pharm Biopharm (2013) 0.75

Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives. J Pharm Pharmacol (2004) 0.75